Manufacturer of Controlled Substances; Notice of Application, 20718 [E8-8165]
Download as PDF
<![CDATA[
20718
Federal Register / Vol. 73, No. 74 / Wednesday, April 16, 2008 / Notices
Drug
Schedule
Oxycodone (9143) .......................................................................................................................................................................................
Oxymorphone (9652) ...................................................................................................................................................................................
Pentobarbital (2270) ....................................................................................................................................................................................
Phenazocine (9715) ....................................................................................................................................................................................
Phencyclidine (7471) ...................................................................................................................................................................................
Phenmetrazine (1631) .................................................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
Piminodine (9730) .......................................................................................................................................................................................
Powdered opium (9639) ..............................................................................................................................................................................
Racemethorphan (9732) ..............................................................................................................................................................................
Racemorphan (9733) ...................................................................................................................................................................................
Remifentanil (9739) .....................................................................................................................................................................................
Secobarbital (2315) .....................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Thebaine (9333) ..........................................................................................................................................................................................
jlentini on PROD1PC65 with NOTICES
The company plans to import small
quantities of the listed controlled
substances for the National Institute on
Drug Abuse (NIDA) for research
activities.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEAto manufacture such
basic classes of controlled substances
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, Virginia 22152; and
must be filed no later than May 16,
2008.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: April 9, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–8177 Filed 4–15–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 14, 2008,
Research Triangle Institute, Kenneth H.
Davis Jr., Hermann Building, East
Institute Drive, P.O. Box 12194,
Research Triangle, North Carolina
27709, made application by renewal to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedules I and II:
Drug
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) ......
Cocaine (9041) .............................
I
I
II
The Institute will manufacture small
quantities of cocaine and marihuana
derivatives for use by their customers in
analytical kits, reagents, and reference
standards as directed by the National
Institute on Drug Abuse.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 16, 2008.
Dated: April 9, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–8165 Filed 4–15–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 18, 2008,
Aldrich Chemical Company Inc., DBA
Isotec, 3858 Benner Road, Miamisburg,
Ohio 45342–4304, made application by
renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Schedule
Cathinone (1235) .........................................................................................................................................................................................
Methcathinone (1237) ..................................................................................................................................................................................
N-Ethylamphetamine (1475) ........................................................................................................................................................................
VerDate Aug<31>2005
19:08 Apr 15, 2008
Jkt 214001
PO 00000
Frm 00111
Fmt 4703
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Sfmt 4703
E:\FR\FM\16APN1.SGM
16APN1
I
I
I
]]>Agencies
[Federal Register Volume 73, Number 74 (Wednesday, April 16, 2008)]
[Notices]
[Page 20718]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-8165]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 14, 2008, Research
Triangle Institute, Kenneth H. Davis Jr., Hermann Building, East
Institute Drive, P.O. Box 12194, Research Triangle, North Carolina
27709, made application by renewal to the Drug Enforcement
Administration (DEA) as a bulk manufacturer of the basic classes of
controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)............................ I
Tetrahydrocannabinols (7370)................ I
Cocaine (9041).............................. II
------------------------------------------------------------------------
The Institute will manufacture small quantities of cocaine and
marihuana derivatives for use by their customers in analytical kits,
reagents, and reference standards as directed by the National Institute
on Drug Abuse.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office
of Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than June 16, 2008.
Dated: April 9, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-8165 Filed 4-15-08; 8:45 am]
BILLING CODE 4410-09-P
